Benzinga | Jul 30, 2021 09:51AM EDT

Chardan Capital Maintains Buy on CRISPR Therapeutics, Lowers Price Target to $171

Chardan Capital analyst Geulah Livshits maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and lowers the price target from $175 to $171.